Table 2.
Clinical Trials of Modulating Gut Microbiota for MS
| Study Detail | Intervention | Results | |
|---|---|---|---|
| Relapsing-remitting MS (n=9), healthy controls (n=13); evaluations prior to, at discontinuation, and three months post-therapy. |
VSL3 Probiotic: 3×1011 CFU /g, 8 strains— 4 Lactobacillus, 3 Bifidobacterium, 1 Streptococcus. |
MS:Intermediate monocytes↓ MS:HLA-DR on dendritic cells↓ MS:Anti-inflammatory response halted post-probiotic |
162 |
| Relapsing-remitting MS patients on interferon beta-1α: probiotic (n=30); placebo comparison(n=30) |
Probiotic: 2×109 CFU /g, L. acidophilus, L. casei, B. bifidum, L. fermentum. |
Probiotic: EDSS↓Probiotic: high-sensitivity CRP serum level↓ | 163 |
| Relapsing-remitting MS patients on interferon beta-1α: probiotic (n=24); placebo comparison(n=24) |
Probiotic:2×109 CFU /g, B. infantis, B. lactis, L. reuteri, L. casei, L. plantarum, L. fermentum |
Probiotic: EDSS↓Probiotic: IL-6↓, IL-10↑ | 164 |
| Secondary progressive MS (n=1) | FMT from her partner | EDSS score stabilized | 165 |
| MS (n=179), healthy controls (n=68); |
SCFAs: propionic acid for 14 days | Tregs induction and function↑ | 166 |
Note: “↑” for increase, “↓” for decrease.
Abbreviation: EDSS, Expanded Disability Status Scale.